OS Therapies Inc. OSTX 深 沪
等待开盘 08-13 09:30:00 美东时间
1.78
+0.110
+6.59%
华盛通- 最 高1.78
- 今 开1.69
- 成交量 30.89万股
- 最 低 1.67
- 昨 收 1.67
- 总市值 5001.39万
- 52周最高 7.00
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 1.12
- 委 比 0.00%
- 总股本 2809.77万
- 历史最高 7.00
- 量 比 0.40
- 振 幅 6.59%
- 历史最低 1.12
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.
08-08 02:32
OS Therapies Raises $4.2M Through Warrant Exercise
An announcement from OS Therapies Incorporated ( ($OSTX) ) is now available. On...
07-14 20:28
OS Therapies Preps for FDA Meeting as It Eyes Accelerated Approval for Rare Bone Cancer Treatment
OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a clinical and global regulatory update on its
07-10 19:49
OS Therapies OST-HER2 Demonstrates 35% 12-Month Event Free Survival With Favorable Safety Profile Compared To 20% Historical Control
The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control (20%)Company also
06-30 18:36
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global ...
06-26 23:44
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.
06-24 20:12
OS Therapies Selects EVERSANA To Support U.S. Commercialization Of OST-HER2, Immunotherapy For Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA®, a leading provider of global
06-10 19:41
OS Therapies Files For Offering Of Up To 7.5M Shares Of Common Stock By Selling Stockholders
-SEC Filing
05-24 04:59
